Nurix Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRIX research report →
Companywww.nurixtx.com
Nurix Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
- CEO
- Arthur T. Sands
- IPO
- 2020
- Employees
- 286
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $1.42B
- P/E
- -6.12
- P/S
- 19.83
- P/B
- 3.76
- EV/EBITDA
- -4.88
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -139.43%
- Op Margin
- -439.26%
- Net Margin
- -411.37%
- ROE
- -64.21%
- ROIC
- -57.63%
Growth & Income
- Revenue
- $83.98M · 53.95%
- Net Income
- $-264,457,000 · -36.62%
- EPS
- $-3.05 · -5.90%
- Op Income
- $-285,666,000
- FCF YoY
- -44.88%
Performance & Tape
- 52W High
- $22.50
- 52W Low
- $8.20
- 50D MA
- $15.97
- 200D MA
- $14.38
- Beta
- 1.88
- Avg Volume
- 1.09M
Get TickerSpark's AI analysis on NRIX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Silva Paul M | other | 31,250 |
| May 15, 26 | Saltzman Edward C | other | 31,250 |
| May 15, 26 | Reinsdorf Judith A | other | 31,250 |
| May 15, 26 | Lacey David L. | other | 31,250 |
| May 15, 26 | Kapur Anil | other | 31,250 |
| May 15, 26 | DANSEY ROGER D | other | 31,250 |
| May 15, 26 | Baynes Roy D. | other | 31,250 |
| May 15, 26 | GREGORY JULIA P | other | 31,250 |
| May 5, 26 | van Houte Hans | sell | 13,473 |
| May 5, 26 | van Houte Hans | sell | 582 |
Our NRIX Coverage
We haven't published any research on NRIX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NRIX Report →